BILS
request access

the Circle. · BILS 2027 · Berlin

From the cell line. To the patient.

What scales.

What purifies.

Who manufactures the future.

10–11 February 2027 Hotel Palace Berlin By invitation · up to 150 senior leaders
Why · The Premise

Why.

Less noise. More signal.

01

Every biologics leader is asked the same question. How does discovery become medicine at scale. With the platform that holds. The infrastructure between candidate and patient is being rebuilt.

02

The white space is the room that holds the conversation differently. Closed-door. By invitation. End-user led. No expo hall. No vendor pitch. A circle for the leaders building what comes next.

03

the Conversation. BILS is that room. Senior biologics leadership convened around the work that compounds. Upstream. Downstream. CDMO. Digital manufacturing and supply. Less noise. More signal.

04

Who attends. Senior faculty drawn from the leaders who own the plant, sign the batch and carry the accountability. Announced in cadence with the programme.

Thesis · The Room

Who manufactures
the future.

Bio Innovation Leaders Summit 2027

10–11 February 2027 Hotel Palace Berlin Invited Audience Only

For decision makers from small biotech to large pharma.

The gap.

Biology moves faster than the infrastructure designed to carry it. Process validation still needs a human signature. The recommendation behind it is now algorithmic. Viral safety clearance follows predictive models. Sterile filtration integrity is monitored by systems that outrun the operator. The compliance gap between model output and accountability has never been formally named.

The Conversation.

BILS convenes the leaders building the infrastructure that closes that gap · across upstream bioprocessing · downstream purification · CDMO strategy · digital manufacturing and supply. The corridor where biologics ambition becomes clinical supply · or breaks. The Conversation is where the leaders who carry the accountability meet before the inspection does.

The decision.

What scales. What purifies. Who manufactures the future. Three questions the room must hold before the process locks. For the leaders who own the plant, sign the batch and are accountable for the intelligence layer no one has formally governed.

Uwe Gottschalk

Conference Chair · Operating Partner, Keensight Capital

In the Conversation

The leaders.

Faculty announced in cadence with the programme.

Uwe Gottschalk · Forum Chair · Bio Innovation Leaders Summit · Berlin

The room.

Bio Innovation Leaders Summit · Berlin · 2027

"

Not an event. It is a tradition.

Uwe Gottschalk · Former CSO Lonza · Operating Partner, Keensight Capital

the circle. forum · in the room

Where it convenes.

bils.ai · the years before · by GBX Circle

photo from the circle forum, in the room, showing Nuno Fontes of WuXi Biologics in conversation, BILS in the room · BILS
photo from the circle forum, the room assembled, GBX Circle forum delegates the room · GBX Circle
photo from the circle forum, keynote on stage, BILS, Bio Innovation Leaders Summit keynote · BILS
the circle. forum · Invited to the Room

The room.

By invitation. By relevance. By room.

Up to

150

senior leaders

Ratio

80/20

end-user · partner

Format

Two
days

closed-door

Seniority

70%+

named principals

By invitation. By relevance. By room.

Invited · By Role

VP Bioprocess Development
Head of Downstream Processing
VP Quality & Compliance
SVP Digital Manufacturing
Head of Process Development
Director of Viral Safety
VP Manufacturing Operations
Head of CMC · Biologics
Chief Technical Officer

Invited · By Organisation

  • Novo Nordisk · AstraZeneca · Roche · Sanofi
  • Boehringer Ingelheim · GSK · MSD · Merck KGaA
  • Pfizer · UCB · AbbVie · Novartis · Bayer · Amgen
  • Lonza Biologics · Samsung Biologics · WuXi Biologics
  • Fujifilm Diosynth · Rentschler · Charles River · Catalent
  • Cytiva · Sartorius · Thermo Fisher Scientific · MilliporeSigma
Partners · Who attends.

The organisations.

BILS 2027 · Berlin.
Who attends.

Asahi Kasei Roche SGS Boehringer Ingelheim GSK Bayer MSD Lundbeck Novo Nordisk Bristol Myers Squibb UCB Cytiva Hamilton Ypso-Facto WuXi Biologics Eleva Biologics EMP Generate Biomedicines Genscript GEA Intertek Keensight Capital Uncountable Wiley Antleron Cabaletta Bio Kyverna Therapeutics Legend Biotech Almirall Tetraneuron

the circle. forum · Partner Positions

By request.
By invitation.

Partner packages and investment are shared directly.
Enter your access code to continue.

No access code? Request the prospectus →

Relationship · The Year

The year.

Not the forum. The relationship.

Q 1

The briefing.

Pre-forum strategic briefing. The room. The roster. The reason.

Q 2

The forum.

BILS held inside each forum of the Conversation. Two days. Closed-door. End-user led.

Q 3

The follow.

Named delegate follow-through. Curated meeting introductions.

Q 4

The intelligence.

Quarterly intelligence briefing from the Conversation Team.

A position. Not a placement.

the circle. · access

BILS 2027 · Request Access

The room
is taking
shape.

The prospectus is not public. Shared directly with the organisations that belong Who attends.

"Not an event. It is a tradition."

Uwe Gottschalk · Former CSO Lonza

Contact · For the Conversation

The conversation.

The room. The conversations. The decisions.

Manager · Life Sciences

Herbert Ryan

Life Sciences · BILS

Co-Producer & Operations

Sheryll Lusk

Operations · the circle.